June 2019 Issue
CE & Training
New estrogen/progesterone combination for vasomotor symptoms due to menopause.
A sclerostin inhibitor for treatment of postmenopausal osteoporosis in patients at high risk for fracture.
An oral inhalation formulation for intermittent OFF episodes in Parkinson's disease patients.